SCHEMBL3410089

SCHEMBL3410089

CC(C)(C)OC(=O)N1CCC(NC(=O)Nc2ccc3nc(N[C@@H]4CCc5ccccc54)ccc3c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
NAMPT P43490 3/20 0.44
EPHX2 P34913 2/20 0.44
USP30 Q70CQ3 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
ALDH1A1 P00352 2/20 0.41
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EPHX1 P07099 1/20 0.40
FPR2 P25090 1/20 0.40
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3413459 0.92 EPHX2 (0.47) EPHX2NPC1ALDH1A1MAPT
SCHEMBL3408455 0.88 EPHX2 (0.46) EPHX2NPC1ALDH1A1MAPTLMNA
SCHEMBL3412407 0.86 JAK2 (0.47) EPHX2NPC1RAB9AALDH1A1MAPT
SCHEMBL3415721 0.85 EPHX2 (0.50) EPHX2
SCHEMBL3410853 0.85 ALDH1A1 (0.51) EPHX2NPC1ALDH1A1MAPTLMNA
SCHEMBL3415079 0.85 EPHX2 (0.42) EPHX2NPC1RAB9AALDH1A1MAPT
SCHEMBL3415823 0.85 EPHX2 (0.51) EPHX2
SCHEMBL3413540 0.83 RAB9A (0.50) EPHX2NPC1RAB9AALDH1A1EPHX1
SCHEMBL3408559 0.83 CXCR3 (0.47) EPHX2NPC1ALDH1A1MAPT
SCHEMBL4109188 0.83 CXCR3 (0.44) EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A CA12 4879/4885CA1 4593/4885CA2 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.